Sheri Rudberg is the co-founder and CEO of WovenX Health, a Chicago-based digital health company that pairs specialty-trained virtual care teams with an AI-native platform to fix the brutal wait times patients face for gastroenterology and other specialty care. A lawyer and operator by training - Georgetown Law, a Northwestern MBA, and years running a $100M business at Hillrom - she started the company (originally Telebelly Health) after watching her own family struggle to get specialist appointments. WovenX partners with brick-and-mortar practices and health systems rather than competing with them, aiming to turn months-long backlogs into care delivered in minutes.
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.
Scott Schorer is CEO and Chairman of G-Tech Medical, a Mountain View startup building GutTracker, a wireless dermal-patch system that reads the body's gut signals at home over days instead of hours. A Dartmouth-trained engineer and former 82nd Airborne infantry officer, he has spent two decades founding, turning around and selling medical-device companies, raising more than $120 million in equity and earning his name on six patents along the way.
G-Tech Medical builds the GutTracker, a thin wireless wearable patch its team calls an 'EKG for the Gut.' Worn on the abdomen for up to six days at home, the patch reads the faint electrical signals that drive the stomach, small intestine, and colon, then streams them over Bluetooth to the cloud, where algorithms turn the noise into patient-specific motility data. The Mountain View company aims to replace short, single-organ, in-clinic tests with continuous, whole-gut measurement so physicians can finally see how a digestive system actually behaves day to day.
Asit Parikh is a physician-scientist turned biotech chief executive who runs MOMA Therapeutics, a Cambridge, Massachusetts company built around the idea of systematically drugging molecular machines - the highly dynamic, shape-shifting proteins that most drug hunters avoid. An MD-PhD trained at Vanderbilt with clinical roots in gastroenterology, he spent two decades at Millennium and Takeda, where he helped steer the inflammatory bowel disease drug vedolizumab (Entyvio) from research to global blockbuster, before taking the CEO seat at MOMA in 2021. He has since raised a $150 million Series B and signed a roughly $2 billion partnership with Roche to push precision cancer medicines toward the clinic.
Oshi Health is a virtual-first gastrointestinal care clinic that gives the roughly one in four Americans living with digestive disorders fast access to a coordinated team of GI providers, registered dietitians, behavioral health specialists, and care coordinators. Available in all 50 states as an in-network benefit, Oshi pairs unlimited virtual visits and messaging with evidence-based, whole-person treatment - an approach a national health plan's analysis tied to 92% symptom improvement, 98% patient satisfaction, and more than $10,000 in medical cost savings per patient over six months.
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.